RxDoctor Payments Data

Mazen Albaghdadi, MD

Interventional Cardiology · Naples, FLNPI 1851557136

Payments from drug & device makers

$226,187in general payments, 2019–2025

Across 183 payments — averaging $1235.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$103K
  • E.r. Squibb & Sons, L.L.C.$58K
  • Boston Scientific$41K
  • Edwards Lifesciences$8K
  • ZOLL Circulation Inc$5K
  • Siemens Medical Solutions USA, Inc.$3K
  • plus $9K from 27 others
$360in research payments, 2019–2025

Across 1 payment — averaging $360.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • ZOLL Circulation Inc$360

What the payments were for

  • Consulting fees$13,73442%
  • Speaking & faculty fees$2,3007%
  • Travel & lodging$4,86415%
  • Food & beverage$11,47435%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$226,187 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$246,951
Medicare patients
760
Services billed
1,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban117$159,921
FarxigaDapagliflozin Propanediol174$149,920
JardianceEmpagliflozin99$102,468
EntrestoSacubitril/Valsartan65$76,790
OzempicSemaglutide36$36,045
BrilintaTicagrelor22$22,855
Repatha SureclickEvolocumab17$21,241
Praluent PenAlirocumab24$13,346
Metoprolol Succinate300$3,442
Atorvastatin Calcium178$2,101
Rosuvastatin Calcium206$1,961
ClopidogrelClopidogrel Bisulfate115$1,735
Spironolactone129$1,358
Bumetanide32$1,046
Colchicine28$958

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$386$172,775196 claims
PfizerEliquis$201$159,921117 claims
Boehringer IngelheimJardiance$27$102,46899 claims
NovartisEntresto$45$76,79065 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →